Sanofi (SNY) Intangibles (2009 - 2026)
Sanofi (SNY) posted Intangibles of $30.6 billion for Q2 2026, little changed sequentially from $30.6 billion in Q4 2025, and up 32.48% YoY from $23.1 billion in Q2 2025.
Sanofi (SNY) Intangibles (2009 - 2026) Analysis & Trends
Sanofi has reported Intangibles for 18 years, with the latest figure at $30.6 billion in Q2 2026.
- Quarterly Intangibles rose 32.48% year-over-year to $30.6 billion in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $30.6 billion (up 32.48% YoY) and the FY2025 annual result came in at $30.6 billion, up 26.42% from the prior year.
- Intangibles held at $30.6 billion in Q2 2026 per SNY's latest filing, from $30.6 billion in the prior quarter.
- Over five years, Intangibles peaked at $30.6 billion in Q2 2026 and troughed at $22.1 billion in Q4 2022.
- A 5-year average of $26.2 billion and a median of $26.2 billion in 2023 frame the typical range for Intangibles.
- The sharpest annual moves came in 2025 and 2026: Intangibles decreased 19.42% in 2025, then surged 32.48% in 2026.
- Over 5 years, Intangibles stood at $22.1 billion in 2022, then grew by 18.51% to $26.2 billion in 2023, then declined by 7.58% to $24.2 billion in 2024, then advanced by 26.42% to $30.6 billion in 2025, then increased by 0.23% to $30.6 billion in 2026.
- According to Business Quant data, Intangibles over the past three periods registered $30.6 billion, $30.6 billion, and $23.1 billion for Q2 2026, Q4 2025, and Q2 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Intangibles (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 652.20 Bn | 631.44 Bn | 17.26 Bn | 48.23 Bn |
| 2 | AbbVie | 469.51 Bn | 462.94 Bn | 12.70 Bn | 49.14 Bn |
| 3 | Merck | 376.81 Bn | 369.67 Bn | 12.21 Bn | 24.98 Bn |
| 4 | Novartis Ag | 303.04 Bn | 295.35 Bn | 11.24 Bn | 42.07 Bn |
| 5 | Astrazeneca | 257.61 Bn | 252.71 Bn | 12.86 Bn | 37.72 Bn |
| 6 | Amgen | 237.37 Bn | 223.38 Bn | 7.24 Bn | 20.49 Bn |
| 7 | Gilead Sciences | 181.73 Bn | 178.55 Bn | 6.22 Bn | 14.03 Bn |
| 8 | Pfizer | 159.66 Bn | 147.96 Bn | 10.94 Bn | 47.05 Bn |
| 9 | Gsk | 106.24 Bn | 102.07 Bn | 8.24 Bn | 22.54 Bn |
| 10 | Sanofi | 55.07 Bn | 47.69 Bn | 10.79 Bn | 30.64 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 30.64 Bn |
| Dec 31, 2025 | 30.57 Bn |
| Jun 30, 2025 | 23.13 Bn |
| Dec 31, 2024 | 24.18 Bn |
| Jun 30, 2024 | 28.70 Bn |
| Dec 31, 2023 | 26.17 Bn |
| Jun 30, 2023 | 26.78 Bn |
| Dec 31, 2022 | 22.08 Bn |
| Jun 30, 2022 | 23.45 Bn |
| Dec 31, 2021 | 24.49 Bn |
| Jun 30, 2021 | 23.33 Bn |
| Dec 31, 2020 | 21.87 Bn |
| Jun 30, 2020 | 18.75 Bn |
| Dec 31, 2019 | 4.21 Mn |
| Jun 30, 2019 | 21.46 Bn |
| Dec 31, 2018 | -62.78 Mn |
| Sep 30, 2018 | 87.23 Mn |
| Jun 30, 2018 | 106.22 Mn |
| Mar 31, 2018 | 25.81 Bn |
| Dec 31, 2017 | 15.40 Bn |